A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

• Published in: New England Journal of Medicine Vol. 383; no. 6; pp. 517 - 525
• Main Authors: Boulware, David R, Pullen, Matthew F, Bangdiwala, Ananta S, Pastick, Katelyn A, Lofgren, Sarah M, Okafor, Elizabeth C, Skipper, Caleb P, Nascene, Alanna A, Nicol, Melanie R, Abassi, Mahsa, Engen, Nicole W, Cheng, Matthew P, LaBar, Derek, Lother, Sylvain A, MacKenzie, Lauren J, Drobot, Glen, Marten, Nicole, Zarychanski, Ryan, Kelly, Lauren E, Schwartz, Ilan S, McDonald, Emily G, Rajasingham, Radha, Lee, Todd C, Hullsiek, Kathy H
• Format: Journal Article Web Resource
• Language: English
• Published: United States Massachusetts Medical Society 06.08.2020
• Subjects: Adult; Asymptomatic; Betacoronavirus; Binding sites; Canada; Coronavirus Infections - prevention & control; Coronaviruses; COVID-19; COVID-19 diagnostic tests; Disease transmission; Double-Blind Method; Drug dosages; Enrollments; FDA approval; Female; Humans; Hydroxychloroquine; Hydroxychloroquine - adverse effects; Hydroxychloroquine - therapeutic use; Infections; Inhalation Exposure; Internet; Male; Middle Aged; Occupational Exposure; Original; Pandemics - prevention & control; Pharmacy; Pneumonia, Viral - prevention & control; Post-Exposure Prophylaxis; Prophylaxis; Quarantine; Risk exposure; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Treatment Failure; United States; Canada; United States; United States > US
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa2016638

In this double-blind, randomized trial, 821 asymptomatic persons with a high-risk or moderate-risk exposure to SARS-CoV-2 were assigned to receive hydroxychloroquine or placebo within 4 days after the exposure. No benefit in preventing illness compatible with Covid-19 was found.